AMLN will NOT reach 17 dollars until (maybe) very late 2011. In fact, there is a greater probability that AMLN will reach a 9 handle before then. Why? A.) Because the same boneheads that have been running the company into the ground are still there. B.) The only revenue producing products they have (Symlin and Byetta)have alarmingly dropping sales numbers C.)There is a good chance of dilution coming. D.) Amylin management moves so slowly that *IF* Bydureon achieves approval it will very likely be after Q2 2012. By then Exenatide will be a distant memory in comparison to competing drugs. Bradbury and Kolterman have truly and purely hosed up this company.
When we get some transparency about Amylin's agreed next steps with the FDA. If the FDA agrees that a short TQT Study is only needed, the stock IMO will steadily climb back to $20. If it turns out to be a long drawn out study, I would start looking for an Icahn Sec Filing to come out challenging the company to make changes at the top.